Greenyn Biotechnology , Ltd Overview
Get informed when a big investor buys or sells
+ Follow13.86%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Greenyn Biotechnology , Ltd posts a ROE of 13.86%. That is above the Healthcare sector average of -75.84%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near -75.84% is typical. Greenyn Biotechnology , Ltd's 13.86% is higher that level. That is roughly 118.3% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Greenyn Biotechnology , Ltd's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 13.86%; use YoY and peer views to separate noise from signal.
Context for 6846.TWO's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -75.84%), and (3) consistency with growth and profitability. This page covers the first two; Greenyn Biotechnology , Ltd's other metric pages and overview cover the third.
Judging Greenyn Biotechnology , Ltd against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 13.86% here, then scan peer and history charts to see if the gap is persistent.
